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Background and purpose   Previous surveys in the Netherlands 
have revealed that guidelines regarding orthopedic thrombopro-
phylaxis were not followed and that a wide variation in proto-
cols exists. This survey was performed to assess the current use 
of thromboprophylactic modalities and to compare it with the 
results of a previous survey.
Methods   All departments of orthopedic surgery in the Neth-
erlands were sent a follow-up survey on venous thromboprophy-
laxis, and the data obtained were compared to the results of a 
survey performed 5 years earlier.
Results   All departments used pharmacological thrombopro-
phylaxis following arthroplasties of the hip and knee. Low-molec-
ular-weight heparin (LMWH) was used most frequently (79%) 
of  the  departments,  followed  by  fondaparinux  (13%).  5  years 
earlier,  coumarin  treatment  was  the  predominant  prophylaxis 
(79%). All departments prescribed pharmacological prophylaxis 
after femoral and tibial fractures; 78% used LMWH. Prophylaxis 
was continued for 6 weeks in 85% of cases. LMWH treatment 
was initiated on the day before surgery in 31% of cases (65% in 
the previous survey), perioperatively in 55%, and in the evening 
following surgery in 24%. In general, for daycare surgery and 
arthroscopies either no prophylaxis was given or a LMWH was 
given for 1 day. After anterior cruciate ligament reconstruction, 
94% of departments prescribed some form of pharmacological 
prophylaxis.
Interpretation   The use of pharmacological prophylaxis after 
arthroplasty of the hip and knee and also after fracture surgery 
around the hip and knee is common practice in the Netherlands. 
In 5 years, the widely used coumarin derivates have been largely 
replaced with LMWH. 

Deep vein thrombosis (DVT) and pulmonary embolism (PE) 
are  common  complications  after  orthopedic  surgery,  espe-
cially after arthroplasties and fracture surgery (Geerts et al. 
2004). Dutch national guidelines (Büller et al. 2000) have not 
been followed (Schonenberg et al. 2003, Ettema et al. 2005). 
Since more attention has been drawn to thromboprophylaxis 
and new pharmacological modalities have been introduced, 
we conducted this survey to assess the current situation. We 
also compared it with the results of a survey from 5 years ear-
lier (Ettema et al. 2005). As in that study, we concentrated on 
hip and knee arthroplasties. Additional questions were asked 
regarding daycare, short stay, fractures, and plaster cast immo-
bilization.
 
Methods
A questionnaire on orthopedic departmental protocols for peri-
operative thromboprophylaxis was sent to all Dutch orthopedic 
departments. It was tailored to fit a similar one performed in 
2002 (Ettema et al. 2005). Practice profile, and current choice, 
initiation, and duration of thromboprophylaxis after several 
orthopedic procedures were assessed.
In 2007, a package with the questionnaire, a cover letter, and 
a stamped addressed envelope were sent to all Dutch ortho-
pedic  departments.  Non-respondents  were  sent  a  reminder 
after 4 months, and were contacted by telephone if necessary. 
Categorical data and dichotomous variables were summarized 
as percentages of the responding departments. For key fea-
tures, the results were compared with those in the 2002 data-
base, which had a response rate of 84 out of 110 departments 
(79%). 
Results
81 of 96 departments answered the questionnaire properly. All 
respondents stated that they had a specific departmental proto-
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Hip and knee arthroplasty
All  departments  used  pharmacological  thromboprophylaxis 
during hospital admission after hip and knee arthroplasties 
(Table  1).  Low–molecular-weight  heparin  (LMWH)  mono-
therapy had replaced vitamin K antagonist (VKA) as the pre-
dominant agent used by the responding departments in 2007 
after elective hip and knee arthroplasty. 
In all departments, coumarines (when prescribed) were com-
bined with a LMWH during the first days of treatment until 
an  adequate  internationalized  normalized  ratio  (INR)  was 
reached. The synthetic Xa inhibitor fondaparinux was given 
in 13% of hip and knee arthroplasties. Since fondaparinux was 
not available during the survey 5 years earlier, no comparison 
can be made. None of the respondents used aspirin. LMWH 
prophylaxis was given after discharge for 3–4 weeks in 9% of 
patients/departments, 6 weeks in 85%, and 2–3 months in 6%. 
Coumarines were continued for 6 weeks in 60% of patients/
departments and 3 months in 40%. 5 years earlier, coumarins 
had been continued for 3 months in 65% of cases/departments. 
In  the  present  study,  fondaparinux  was  prescribed  for  3–4 
weeks in 55% of patients/departments and 5–6 weeks in 45%. 
Fractures of the proximal femur and tibia
All  departments  used  pharmacological  prophylaxis  after 
osteosynthesis or arthroplasty of hip and proximal femur frac-
tures, and after internal fixation of proximal tibia fractures 
(Table 2). In 2007, as with elective arthroplasties, LMWH had 
come to replace coumarins as the mainstay of thromboprophy-
laxis after hemiarthroplasty of the hip (compared to 5 years 
earlier). Prophylaxis was continued for 4–6 weeks in 88% 
of patients/departments and for 2–3 months in 9%. In 2007 
thromboprophylaxis was not continued after discharge in 3% 
of the departments, which was less than in 2002 (9%).
Initiation of treatment
LMWH treatment was started on the evening before surgery in 
31% of patients/departments, 2 h preoperatively in 23%, less 
than 6 h postoperatively in 22%, and in the evening following 
surgery (regardless of the time of surgery) in 24% of patients/
departments. In 2002, 65% of all LMWH therapy was started 
on the evening before surgery and in 21% of cases/departments 
it was started 2 h preoperatively. Coumarins were started on 
the day of surgery in 46% of patients/departments and later in 
54%. Fondaparinux was always initiated 6–12 hours postop-
eratively (as recommended by the manufacturer).
Day care, arthroscopy, and anterior cruciate ligament 
(ACL) reconstruction
When treating patients in daycare surgery (including arthros-
copy of the knee), compared to 5 years earlier an increased 
number of departments did not use any prophylaxis in 2007 
(Table 3). After ACL reconstruction 50% of departments used   
a LMWH for 1–3 days (or the period of admission), 5% for 
1 or 2 weeks, 2% for 3–4 weeks, and 35% of departments 
Table 1. Thromboprophylactic regimens used after elective arthroplasties (%)
  In hospital only   In hospital and extended thromboprophylaxis
Arthroplasty   LMWH    LMWH   LMWH and VKA’s a   fondaparinux   Aspirin 
  2002   2007   2002   2007   2002   2007   2002   2007   2002   2007
Total hip   2  None  17   79   80   7  NA   14   1  0
Revision hip   2  None  16   80   81   7   NA   13   1   0
Total knee   2  None  20   79   77   8   NA   14   1   0
Revision knee   2  None  18   80   79   7   NA   13   1   0
Hemi knee   9  3  8   78   82   7   NA   12  1   0
Average   3  1  17   79   79   7   NA   13   1  0
a LMWH until adequate INR was reached; in 2002, 12% of departments used a coumarin only. 
Table 2. Thromboprophylactic regimens used after fracture surgery. Values are percentages
  In hospital only  In hospital and extended out-of-hospital thromboprophylaxis
  
    LMWH  LMWH and VKA’s a  fondaparinux 
Trauma procedure  2002   2007   2002   2007   2002   2007   2002   2007
Hemi hip arthroplasty    9   3  15  78  75  9    10
Hip, internal fixation      1    81    9    9
Proximal femur, internal fixation     4    78    8    10
Proximal tibia, internal fixation    12    79    8    5
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used LMWH prophylaxis for 6 weeks. 1 hospital prescribed 
fondaparinux for 2 weeks. Another hospital used a coumarin 
for 6 weeks. No form of prophylaxis was given in 6% of cases/
departments.
Plaster cast immobilization (Table 4)
During lower leg immobilization, some form of pharmaco-
logical prophylaxis was given in 70% of cases/departments. 
During immobilization of both knee and ankle, thrombopro-
phylaxis was used in 94% of the departments. In 2002, most 
departments prescribed a coumarin derivate but by 2007 this 
had generally been replaced with a LMWH. 
NSAIDs, aspirin and coumarins
83% of the departments discontinued aspirin for 3–10 days 
before surgery. Continued use of aspirin until the day of sur-
gery was a reason for delayed surgery in 26% of these depart-
ments. NSAIDs were discontinued for 2–10 days before sur-
gery in only 40% of the hospitals; non-compliance with this 
protocol was a reason for cancellation of surgery in only 10% 
of the departments. Coumarin therapy was interrupted in all 
departments for 2–10 days. Patients were managed with vita-
min K or clotting factor infusions in 58% of departments, or 
surgery was delayed when it was not discontinued (42% of 
departments).
Mechanical prophylaxis
In  addition  to  pharmacological  prophylaxis,  some  hospi-
tals used mechanical prophylactic devices. Elastic stockings 
were used after total hip arthroplasty in 8% of departments 
as compared to 20% in 2002, and after knee arthroplasty in 
5% of departments as compared to 11% previously. Intermit-
tent pneumatic compression was not employed in any of the 
departments that responded to the questionnaire.
Of all the departments, 93% did not prescribe any standard 
prophylaxis for patients below 16 years of age, 5% treated 
these patients as adults, and 2% had a more complicated pro-
tocol.
The  most  frequently  prescribed  LMWH  was  nadroparin 
(76%), followed by dalteparin (19%) and enoxaparin (5%) in 
their standard prophylactic doses (98%). This has not changed 
appreciably in 5 years.
 
Discussion
Our  follow-up  survey  reveals  that  within  5  years,  vitamin 
K antagonists have been largely replaced with LMWH and 
fondaparinux for the prevention of venous thromboembolic 
events  (VTEs)  in  orthopedic  surgery  in  the  Netherlands. 
There is still considerable variation in protocols among dif-
ferent departments. The Dutch consensus document “Deep 
venous thrombosis and pulmonary embolism” recommends 
thromboprophylaxis with a LMWH for a period of 6 weeks 
after major orthopedic surgery of the hip and knee, and VKA 
is considered an alternative only (Büller et al. 2000). Gener-
ally, a LMWH is prescribed after arthroplasty of the hip and 
knee; this shows that compliance with the consensus is better 
than in the previous two surveys (Schonenberg et al. 2003, 
Ettema et al. 2005). Since the consensus originated in 2000, 
it does not include new anticoagulants such as fondaparinux. 
Newer guidelines (Geerts et al. 2004) do favor fondaparinux 
after arthroplasty and hip fracture surgery. Clearly, a consid-
erable number of orthopedic departments have looked ahead 
and introduced these synthetic agents before any new national 
guidelines appear. We believe these results are representative 
because of the high response rate. 
We found that LMWH is generally started perioperatively 
(between 2 h before and 6 h after surgery) in the Netherlands. 
The remaining departments start either on the day before or 
the evening after surgery. It appears that a preoperative start 
is no more effective than a postoperative start (Strebel et al. 
2002). A perioperative start is apparently more effective, but 
this is counterbalanced by a marked increase in the risk of 
Table 3. Thromboprophylactic regimens used after daycare surgery 
and knee arthroscopy (%)
   No prophylaxis   LMWH once or    Other 
    during admission
Procedure  2002  2007   2002  2007  2002  2007
Day-care   40  64   59   34 a   0   2 c
Arthroscopy   40   4   59   49 b   1  3 d
a 54% initiation preoperatively, 
b 52% initiation preoperatively, 
c 1 department used fondaparinux for 2 weeks and 1 LMWH for 5 
days, 
d 1 department used LMWH for 5 days, 1 department recommended 
6 weeks of vitamin K antagnist as prophylaxis and 1 department 
recommended 14 days of fondaparinux.
Table 4. Thromboprophylactic regimens used with immobilization of the lower extremity (%)
    No prophylaxis   LMWH  LMWH without    fondaparinux   coumarin 
Type of      weight bearing
immobiliszation  2002   2007   2002   2007   2002   2007   2002   2007   2002   2007
Below the knee only   50   30   10   52   3   13   NA   4   37   1
Above the knee and ankle    11   6   16   84   5   5   NA   3   68   2112  Acta Orthopaedica 2009; 80 (1): 109–112
major bleeding in comparison with a preoperative or postop-
erative regimen (Strebel et al. 2002). Although international 
guidelines advise against the use of spinal and epidural blocks 
in patients on LMWH perioperatively (Horlocker et al. 2003), 
the Dutch practice does not contradict the Dutch guidelines 
for single-shot spinal anesthesia (De Lange et al. 2004). 
Extended  pharmacological  thromboprophylaxis  is  stan-
dard after hip and knee arthroplasty and hip fracture surgery. 
A meta-analysis showed a favorable effect of LMWH with a 
reduction in total thrombosis after hip arthroplasties (asymp-
tomatic as well as symptomatic) when compared to placebo 
or no prophylaxis after 30–42 days of treatment. The data 
regarding knee arthroplasty are less obvious (Eikelboom et al. 
2001).
Although favorable results have been reported in a number of 
studies with mechanical methods of prophylaxis (Kaempffe et 
al. 1991, Francis et al. 1992), pneumatic compression devices 
were no longer used by the responders in our study. Elastic 
stockings are used, but only as an adjuvant to a pharmacologi-
cal regimen.
The use of prophylaxis after smaller procedures such as 
arthroscopy of the knee or ACL reconstruction remains con-
troversial (Nurmohamed 2007, Verheyen 2007); the risk after 
arthroscopy of the knee appears to be low (Ettema et al. 2006, 
Hoppener et al. 2006) whereas the risk of thrombosis after 
ACL reconstruction is unknown. This uncertainty is reflected 
in the wide variation in regimens following these procedures 
in the responding departments. Much of the same applies to 
plaster cast immobilization: the national guidelines recom-
mend the use of prophylaxis after above–the-knee casts, but 
not with below-knee casting. Furthermore, the ACPP consen-
sus statement does not recommend routine prophylaxis with 
below-knee fractures (Geerts et al. 2004). Even so, a recent 
meta-analysis  of  randomized  controlled  trials  investigating 
thromboprophylaxis  with  plaster  cast  immobilization  has 
shown a favorable effect of LMWH on asymptomatic end-
points (Ettema et al. 2008).
In summary, the use of pharmacological prophylaxis after 
arthroplasty of the hip and knee and also after fracture sur-
gery around the hip and knee is common practice in the Neth-
erlands. Generally speaking, it is continued after discharge. 
LMWH or fondaparinux is mainly used, whereas 5 years ago 
coumarin derivates were the preferred treatment. There still 
remains a wide variability in regimens after smaller proce-
dures such as arthroscopy and ACL reconstruction and after 
immobilization of the leg. 
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